

# Silvia Martinelli

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3763276/publications.pdf>

Version: 2024-02-01

40  
papers

757  
citations

516710

16  
h-index

526287

27  
g-index

40  
all docs

40  
docs citations

40  
times ranked

1352  
citing authors

| #  | ARTICLE                                                                                                                                                                                                                                                                                    | IF   | CITATIONS |
|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 1  | The monocytic population in chronic lymphocytic leukemia shows altered composition and deregulation of genes involved in phagocytosis and inflammation. <i>Haematologica</i> , 2013, 98, 1115-1123.                                                                                        | 3.5  | 92        |
| 2  | Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia. <i>Oncotarget</i> , 2016, 7, 65968-65981.                                                                                                                                               | 1.8  | 84        |
| 3  | Angiotensin-2 plasma dosage predicts time to first treatment and overall survival in chronic lymphocytic leukemia. <i>Blood</i> , 2010, 116, 584-592.                                                                                                                                      | 1.4  | 51        |
| 4  | Targeting neoplastic B cells and harnessing microenvironment: the "double face" of ibrutinib and idelalisib. <i>Journal of Hematology and Oncology</i> , 2015, 8, 60.                                                                                                                      | 17.0 | 49        |
| 5  | Increased angiogenesis induced by chronic lymphocytic leukemia B cells is mediated by leukemia-derived Ang2 and VEGF. <i>Leukemia Research</i> , 2010, 34, 312-321.                                                                                                                        | 0.8  | 48        |
| 6  | Gene expression profiling of acute promyelocytic leukaemia identifies two subtypes mainly associated with Flt3 mutational status. <i>Leukemia</i> , 2006, 20, 103-114.                                                                                                                     | 7.2  | 42        |
| 7  | Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia. <i>Haematologica</i> , 2015, 100, 253-262.                                                                                                                                    | 3.5  | 40        |
| 8  | Endothelin-1 Promotes Survival and Chemoresistance in Chronic Lymphocytic Leukemia B Cells through ETA Receptor. <i>PLoS ONE</i> , 2014, 9, e98818.                                                                                                                                        | 2.5  | 33        |
| 9  | ANGPT2 promoter methylation is strongly associated with gene expression and prognosis in chronic lymphocytic leukemia. <i>Epigenetics</i> , 2013, 8, 720-729.                                                                                                                              | 2.7  | 30        |
| 10 | Physical contact with endothelial cells through $\alpha 1$ - and $\alpha 2$ - integrins rescues chronic lymphocytic leukemia cells from spontaneous and drug-induced apoptosis and induces a peculiar gene expression profile in leukemic cells. <i>Haematologica</i> , 2012, 97, 952-960. | 3.5  | 29        |
| 11 | Multiparametric Flow Cytometry for MRD Monitoring in Hematologic Malignancies: Clinical Applications and New Challenges. <i>Cancers</i> , 2021, 13, 4582.                                                                                                                                  | 3.7  | 28        |
| 12 | Clinical heterogeneity of <i>de novo</i> 11q deletion chronic lymphocytic leukaemia: prognostic relevance of extent of 11q deleted nuclei inside leukemic clone. <i>Hematological Oncology</i> , 2013, 31, 88-95.                                                                          | 1.7  | 25        |
| 13 | Endothelium-mediated survival of leukemic cells and angiogenesis-related factors are affected by lenalidomide treatment in chronic lymphocytic leukemia. <i>Experimental Hematology</i> , 2014, 42, 126-136.e1.                                                                            | 0.4  | 23        |
| 14 | Increased expression of angiotensin-2 characterizes early B-cell chronic lymphocytic leukemia with poor prognosis. <i>Leukemia Research</i> , 2008, 32, 593-597.                                                                                                                           | 0.8  | 22        |
| 15 | Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor. <i>Haematologica</i> , 2008, 93, 1252-1255.                                                                                                         | 3.5  | 19        |
| 16 | Idelalisib impairs T-cell-mediated immunity in chronic lymphocytic leukemia. <i>Haematologica</i> , 2018, 103, e598-e601.                                                                                                                                                                  | 3.5  | 16        |
| 17 | Angiotensin-2 expression in B-cell chronic lymphocytic leukemia: association with clinical outcome and immunoglobulin heavy-chain mutational status. <i>Leukemia</i> , 2007, 21, 1312-1315.                                                                                                | 7.2  | 14        |
| 18 | IRF4 modulates the response to BCR activation in chronic lymphocytic leukemia regulating IKAROS and SYK. <i>Leukemia</i> , 2021, 35, 1330-1343.                                                                                                                                            | 7.2  | 13        |

| #  | ARTICLE                                                                                                                                                                                                                                                 | IF  | CITATIONS |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 19 | Immunoglobulin Mutational Status Detected through Single-Round Amplification of Partial VH Region Represents a Good Prognostic Marker for Clinical Outcome in Chronic Lymphocytic Leukemia. <i>Journal of Molecular Diagnostics</i> , 2005, 7, 566-574. | 2.8 | 12        |
| 20 | Lenalidomide in chronic lymphocytic leukemia: the present and future in the era of tyrosine kinase inhibitors. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 97, 291-302.                                                                      | 4.4 | 12        |
| 21 | Notch2 Increases the Resistance to Venetoclax-Induced Apoptosis in Chronic Lymphocytic Leukemia B Cells by Inducing Mcl-1. <i>Frontiers in Oncology</i> , 2021, 11, 777587.                                                                             | 2.8 | 9         |
| 22 | The expression of endothelin-1 in chronic lymphocytic leukemia is controlled by epigenetic mechanisms and extracellular stimuli. <i>Leukemia Research</i> , 2017, 54, 17-24.                                                                            | 0.8 | 8         |
| 23 | Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide. <i>Leukemia and Lymphoma</i> , 2018, 59, 423-433.                                                                                            | 1.3 | 7         |
| 24 | Neoantigen-Specific T-Cell Immune Responses: The Paradigm of NPM1-Mutated Acute Myeloid Leukemia. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9159.                                                                                  | 4.1 | 7         |
| 25 | BTK Inhibitors Impair Platelet-Mediated Antifungal Activity. <i>Cells</i> , 2022, 11, 1003.                                                                                                                                                             | 4.1 | 7         |
| 26 | How to Improve Prognostication in Acute Myeloid Leukemia with CFBF-MYH11 Fusion Transcript: Focus on the Role of Molecular Measurable Residual Disease (MRD) Monitoring. <i>Biomedicines</i> , 2021, 9, 953.                                            | 3.2 | 6         |
| 27 | Indoleamine 2, 3-Dioxygenase 1 Mediates Survival Signals in Chronic Lymphocytic Leukemia via Kynurenine/Aryl Hydrocarbon Receptor-Mediated MCL1 Modulation. <i>Frontiers in Immunology</i> , 2022, 13, 832263.                                          | 4.8 | 6         |
| 28 | IRF4 L116R mutation promotes proliferation of chronic lymphocytic leukemia B cells inducing MYC. <i>Hematological Oncology</i> , 2021, 39, 707-711.                                                                                                     | 1.7 | 5         |
| 29 | Macitentan, a double antagonist of endothelin receptors, efficiently impairs migration and microenvironmental survival signals in chronic lymphocytic leukemia. <i>Oncotarget</i> , 2017, 8, 90013-90027.                                               | 1.8 | 5         |
| 30 | Interferon- $\alpha$ may restore sensitivity to tyrosine kinase inhibitors in Philadelphia chromosome positive acute lymphoblastic leukaemia with F317L mutation. <i>British Journal of Haematology</i> , 2009, 146, 227-230.                           | 2.5 | 4         |
| 31 | Angiopoietin-2 Expression in B-Cell Chronic Lymphocytic Leukemia: Association with Clinical Outcome and Immunoglobulin Heavy-Chain Mutational Status.. <i>Blood</i> , 2006, 108, 2780-2780.                                                             | 1.4 | 4         |
| 32 | NOTCH2 Contributes to Venetoclax Resistance in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2019, 134, 4280-4280.                                                                                                                                       | 1.4 | 3         |
| 33 | A single-tube multiplex method for monitoring mutations in cysteine 481 of Bruton Tyrosine Kinase (BTK) gene in chronic lymphocytic leukemia patients treated with ibrutinib. <i>Leukemia and Lymphoma</i> , 2021, 62, 2018-2021.                       | 1.3 | 2         |
| 34 | In Vitro and in Vivo Evidence of an Anti-Angiogenic Effect of Lenalidomide in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2012, 120, 1782-1782.                                                                                                        | 1.4 | 2         |
| 35 | Angiopoietin-2 acts as a survival factor for chronic lymphocytic leukemia B cells throughout T cell receptor engagement. <i>Hematological Oncology</i> , 2018, 36, 372-375.                                                                             | 1.7 | 0         |
| 36 | Angiopoietin-2 Plasma Dosage Predicts Time to First Treatment (TTFT) and Overall Survival (OS) in Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2009, 114, 1260-1260.                                                                                   | 1.4 | 0         |

| #  | ARTICLE                                                                                                                                                                            | IF  | CITATIONS |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 37 | Lenalidomide Promotes a Pro-Inflammatory Switch of Nurse-like Cells Derived from Chronic Lymphocytic Leukemia. <i>Blood</i> , 2014, 124, 3286-3286.                                | 1.4 | 0         |
| 38 | Ibrutinib Targets Nurse-like Cells Supporting an Immunosuppressive Phenotype in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 613-613.                                   | 1.4 | 0         |
| 39 | Pre-existing cytopenia heralding de novo acute myeloid leukemia: uncommon presentation of NPM1-mutated AML in a single-center study. <i>Leukemia Research</i> , 2021, 111, 106747. | 0.8 | 0         |
| 40 | Indoleamine 2,3-Dioxygenase Mediates Survival of Chronic Lymphocytic Leukemia B Cells through Aryl Hydrocarbon Receptor By Inducing Mcl1. <i>Blood</i> , 2020, 136, 19-19.         | 1.4 | 0         |